GGrantIndex
Sort

23,748 grants matching melanoma

MULTI-TRACER PET ASSESSMENT OF RESPONSE TO NOVEL TARGETED CHEMOTHERAPY

$299,900
John M Hoffman · University Of Utah · R21 · FY2014 · CA

Core 2: Animal and Pharmacology

$299,875
Jann N Sarkaria · Massachusetts Institute Of Technology · U54 · FY2017 · CA

Generation of T-cell receptors recognizing antigens on non-melanoma tumors

$299,849
James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Immunoactivating Peptide AXT201 in Combination with Anti-PD-1 Antibody for Triple-Negative Breast Cancer

$299,815
Niranjan B Pandey · Asclepix Therapeutics, Inc. · R43 · FY2019 · CA

PRECLINICAL STUDY OF PEPTIDE BASED HUMAN TUMOR VACCINES

$299,811
University Of Virginia Charlottesville · R01 · FY2001 · CA

Liver Specific Manganese Based MRI Contrast Agent

$299,811
Vera Hoffman · Reveal Pharma · R44 · FY2019 · CA

Eastern Cooperative Oncology Group

$299,793
Indiana Univ-Purdue Univ At Indianapolis · U10 · FY2004 · CA

Host's Genes that Control Lymphocyte Infiltration of Tumors

$299,776
Peter Demant · Roswell Park Cancer Institute Corp · R01 · FY2010 · CA

Mechanistic Studies on New Platinum Clinical Agents

$299,758
Nicholas P Farrell · Virginia Commonwealth University · R01 · FY2010 · CA

Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy

$299,754
Sahar Usmani-Brown · L2 Diagnostics, Llc · R43 · FY2017 · DK

Dissecting the opposing roles of alpha-3 integrin in metastasis

$299,721
Christopher S. Stipp · University Of Iowa · R01 · FY2011 · CA

Regulation of PTEN Activity in Cancer Cells

$299,712
University Of Arizona · R01 · FY2004 · CA

TCR Affinity and Therapeutic Efficacy of T Cells

$299,698
Michael I Nishimura · Medical University Of South Carolina · R01 · FY2009 · CA

Engineered tumor-specific T cells Resist Hypoxic-Tumor Immunosuppressive Attacks.

$299,690
Patricia Yotnda · Baylor College Of Medicine · R01 · FY2014 · CA

Dissecting the opposing roles of alpha-3 integrin in metastasis

$299,655
Christopher S. Stipp · University Of Iowa · R01 · FY2012 · CA

Use of aAPC for Melanoma Adoptive Immunotherapy

$299,653
Jonathan P Schneck · Johns Hopkins University · R01 · FY2013 · CA

Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancer

$299,639
Panagiotis Konstantinopoulos · Dana-Farber Cancer Inst · P50 · FY2021 · CA

Personalized melanoma chemoprevention

$299,638
Douglas Grossman · University Of Utah · R01 · FY2013 · CA

Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade

$299,607
Emmanuel T Akporiaye · Veana Therapeutics, Llc · R43 · FY2018 · CA

Characterization of Tumor Specific T Cells in Melanoma

$299,564
Stanford University · R01 · FY2002 · CA

Pathways from genotype and environment to melanoma

$299,523
Nicholas K Hayward · Queensland Institute Of Medical Research · R01 · FY2009 · CA

Association of Inherited Variation in Immune Mediated Adverse Events and Respons

$299,473
Katherine L Nathanson · Wistar Institute · P50 · FY2015 · CA

Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy

$299,472
Ashish Ranjan · Oklahoma State University Stillwater · R37 · FY2019 · CA

Prospective Study of the Associations between Cutaneous Papillomavirus and Polyo

$299,359
Dana Elise Rollison · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2015 · CA

A role for c-Abl/Arg in melanoma progression

$299,345
Rina Plattner · University Of Kentucky · R01 · FY2014 · CA